10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares in Akebia Therapeutics finished the day around 6% up on Tuesday, after the firm announced the first ever filing for vadadustat, an investigational oral treatment for anemia due to chronic kidney disease (CKD). 24 July 2019
In a major fillip for cancer biotech Jounce Therapeutics, Celgene has opted to license worldwide rights to JTX-8064, an antibody targeting the LILRB2 receptor on macrophages. 24 July 2019
A set of quarterly financial results that exceeded expectations and led to improved full-year guidance prompted shares in Biogen increasing by 5% in Tuesday morning’s trading. 23 July 2019
A company that calls itself the world-leading AI-driven drug discovery company has entered into a collaboration with Rallybio, a privately-held development-stage biotechnology company focused on rare diseases. 23 July 2019
Germany’s Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the USA to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemophilia A treatment, Jivi, antihemophilic factor (recombinant) PEGylated-aucl 3000 IU. 23 July 2019
Japanese drugmaker Shionogi has entered into an out-licensing agreement on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa, with the UK’s AMR Centre, based in Alderley Park, Cheshire. 23 July 2019
Acadia Pharmaceuticals saw its shares fall 16% to $21.62 in after-hours trading on Monday, after it released disappointing top-line results from its Phase III ENHANCE study. 23 July 2019
A new combination therapy for liver cancer has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration, unlocking expedited development and review by the US regulator. 23 July 2019
As the global medical lead of the Adcetris (brentuximab vedotin) program for Japanese pharma major Takeda, Thanos Zomas’ job was made easier by Phase III trial results that he describes as “almost unprecedented.” 22 July 2019
Israeli biotech firm Intec Pharma (Nasdaq: NTEC) saw its market capitalization plummet after it announced top-line data from the company's pivotal Phase III trial (the ACCORDANCE trial). 22 July 2019
Shares of US biotech firm Durect were up as much as 39% in light pre-market volume today, as it announced a significant collaboration with Gilead Sciences. 22 July 2019
Belgium’s UCB has won approval from China’s National Medical Product Administration (NMPA) for Cimzia (certolizumab pegol), to treat moderate-to-severe rheumatoid arthritis. 22 July 2019
Takeda Pharmaceutical today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic Entyvio (vedolizumab). 22 July 2019
The US Food and Drug Administration (FDA) has approved Otezla (apremilast) 30mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s disease. 20 July 2019
Johnson & Johnson’s pharma business Janssen has submitted to broaden the European label for Darzalex (daratumumab), for subcutaneous treatment of multiple myeloma. 19 July 2019
Gilead Sciences (Nasdaq: GILD) today announced today that it has licensed three pre-clinical antiviral programs, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. 19 July 2019
Cynata Therapeutics has revealed that it has received an indicative, non-binding and conditional proposal from Japan’s Sumitomo Dainippon Pharma regarding a possible acquisition. 19 July 2019
European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new 400 million-euro ($488 million) fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion. 19 July 2019
The US Food and Drug Administration has granted rare pediatric disease designation to LM-030, an investigational therapy licensed from Novartis last year and ready to enter into pivotal clinical trials for the treatment of Netherton syndrome by privately-held rare diseases specialist LifeMax Laboratories. 19 July 2019
USA-based biotech firm MacroGenics has announced that French privately held drugmaker Servier will terminate their collaboration and license agreement entered into seven years ago, with an effective date of January 15, 2020, unless sooner agreed to by the parties. 18 July 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024